Navigation Links
BiOptix Continues Support of Antibody Engineering & Therapeutics Research
Date:12/11/2013

BOULDER, Colo. and HUNTINGTON BEACH, Calif., Dec. 11, 2013 /PRNewswire/ -- BiOptix continues support of the global antibody engineering and therapeutics research community through participation in IBC's 24th Annual Antibody Engineering & Therapeutics Conference and annual meeting of The Antibody Society, being held in Huntington Beach, CA from December 8 – 12, 2013.   During the event, BiOptix will be highlighting the BiOptix Innovators Program, a unique and innovative product evaluation platform that allows customers to try BiOptix SPR technology independently in their lab, on their timeframe and with complete customer and technical support during the process. 

While presenting new antibody kinetics data from BiOptix, Ken Wilczek, Vice President, Sales & Marketing for BiOptix noted: "Antibody research and therapeutics continues to be a vital and growing market worldwide—and is a perfect match for the BiOptix 404pi."  "With a unique platform, multiple sensor chemistries and an industry -leading instrumentation demo initiative known as the BiOptix Innovators Program, BiOptix is becoming a principal choice for antibody researchers who require robust and repeatable kinetics."  Additional details about the BiOptix Innovators Program, in which BiOptix seeks to partner with academic, pharmaceutical and biotechnology/drug discovery research labs can be found at:  http://www.bioptix.com/products/innovators-program

Surface Plasmon Resonance is an advanced and highly sensitive optical technology that measures refractive index changes on a sensor chip's gold surface due to a change in mass that occurs during a binding event. This change can be used to monitor biological interactions such as the concentration of target molecules, kinetic rates and affinity constants. BiOptix has developed and patented a novel ultra-sensitive detection platform known as Enhanced Surface Plasmon Resonance, or ESPR. Unlike traditional SPR, ESPR instrumentation from BiOptix enables the high sensitivity of SPR with the high stability and lower noise of common path interferometry.

About BiOptix

BiOptix Diagnostics is a privately held firm based in Boulder, Colorado, with leading investments from Boulder Ventures, Remeditex and Rusnano.  BiOptix has developed a new class of analytical biosensor instrumentation utilizing a patented high-throughput label-free technology known as ESPR – Enhanced Surface Plasmon Resonance. BiOptix instrumentation allows researchers to study label-free protein-protein and protein-small molecule interaction—with high sensitivity and high throughput. Applications include: Protein-small molecule interactions, protein-protein kinetics, antibody affinities and epitope mapping, oligosaccharide characterization, nucleic acid (DNA-DNA or DNA-RNA) hybridization and biomolecule concentration measurements. Additional information about BiOptix and our products can be found at:  www.bioptix.com

 


'/>"/>
SOURCE BiOptix
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. BiOptix continues support of Colorado-based research institutions
2. Celebrating 65 Years of Providing Superior Healthcare Products, Mission Pharmacal Continues to Thrive
3. UV Flu Technologies Continues Aggressive Program to Pay off Convertible Debt
4. AMPAC Fine Chemicals Continues to Invest in Quality Systems
5. Profil Institute Continues to Publish New Findings in Metabolic Research
6. China Cord Blood Corporation Continues Share Repurchase Program
7. Pressure BioSciences, Inc. Continues Global Sales Reach Expansion with Distribution Agreements for China, Vietnam, Laos, Cambodia, Australia, and New Zealand
8. BioStorage Technologies Continues Global Growth; Announces Strategic Expansion Into Asia Pacific and New General Manager APAC
9. Green Coffee Extract Continues Dominance Amongst Summers Top Weight Loss Products
10. Z Trim Holdings Sales Growth Continues in July 2012
11. Z Trim Holdings Sales Growth Continues in August 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Calif. , June 23, 2016  Blueprint Bio, ... biological discoveries to the medical community, has closed its ... Matthew Nunez . "We have received ... with the capital we need to meet our current ... essentially provide us the runway to complete validation on ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the only free ... and will showcase its product’s latest features from June 26 to June 30, ... poster on Disrupting Clinical Trials in The Cloud during the conference. DIA ...
(Date:6/23/2016)... FRANCISCO , June 22, 2016  Amgen (NASDAQ: ... sponsorship of the QB3@953 life sciences incubator ... human health. The shared laboratory space at QB3@953 was ... overcome a key obstacle for many early stage organizations ... part of the sponsorship, Amgen launched two "Amgen Golden ...
(Date:6/22/2016)... , June 22, 2016 Research and ... Global Markets" report to their offering. ... billion in 2014 from $29.3 billion in 2013. The market is ... of 13.8% from 2015 to 2020, increasing from $50.6 billion in ... projected product forecasts during the forecast period (2015 to 2020) are ...
Breaking Biology Technology:
(Date:4/26/2016)... -- Research and Markets has announced the ...  report to their offering.  , ,     (Logo: ... forecast the global multimodal biometrics market to grow ... 2016-2020.  Multimodal biometrics is being implemented ... healthcare, BFSI, transportation, automotive, and government for controlling ...
(Date:4/14/2016)... , April 14, 2016 ... and Malware Detection, today announced the appointment of ... the new role. Goldwerger,s leadership appointment comes ... the heels of the deployment of its platform at ... behavioral biometric technology, which discerns unique cognitive and physiological ...
(Date:3/29/2016)... LegacyXChange, Inc. (OTC: LEGX ... Protect are pleased to announce our successful effort to ... of writing instruments, ensuring athletes signatures against counterfeiting and ... athletes on LegacyXChange will be assured of ongoing proof ... Bill Bollander , CEO states, "By inserting ...
Breaking Biology News(10 mins):